Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.

Oncotarget - 28 Feb 2017

Kerstjens Mark, Driessen Emma M C, Willekes Merel, Pinhanços Sandra S, Schneider Pauline, Pieters Rob, Stam Ronald W

Abstract excerpt

Acute lymphoblastic leukemia (ALL) in infants is an aggressive malignancy with a poor clinical outcome, and is characterized by translocations of the Mixed Lineage Leukemia (MLL) gene. Previously, we identified RAS mutations in 14-24% of infant ALL patients, and showed that the presence of a RAS mutation decreased the survival chances even further. We hypothesized that targeting the RAS signaling pathway could be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Gene Rearrangement

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Histone-Lysine N-Methyltransferase

Share to MAP Kinase Kinase 1

Share to Myeloid-Lymphoid Leukemia Protein

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to ras Proteins

Share to Translocation, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 27588400
DOI: 10.18632/oncotarget.11730
PMCID: PMC5362448

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.PMID 27588400Read ↗

The role of RAS mutations in MLL-rearranged leukaemia: A path to intervention?Semantic proximity Read ↗

Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.Semantic proximity Read ↗

Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants.Semantic proximity Read ↗

MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemiaSemantic proximity Read ↗

Combining menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.Semantic proximity Read ↗

RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.Semantic proximity Read ↗

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology GroupSemantic proximity Read ↗

Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL -Rearranged Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Efficacy of RMC-6236 (Daraxonrasib) and novel combination strategies targeting resistance in RAS pathway-driven neuroblastomaSemantic proximity Read ↗

Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.Semantic proximity Read ↗

EZH2 inactivation drives MAPK-dependent vulnerability to MEK inhibition in RAS-mutant CMMLSemantic proximity Read ↗

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.